<?xml version="1.0" encoding="UTF-8"?>
<p>There are therapeutic strategies to combat HIV-1 infection in addition to combination antiretroviral therapy, which is currently used to treat HIV-infection [
 <xref rid="B24-molecules-25-02944" ref-type="bibr">24</xref>]. Other approaches to combat HIV-1 infection include novel strategies such as disrupting the 
 <italic>CCR5</italic> gene in human hematopoietic stem/progenitor cells (HSCs) [
 <xref rid="B25-molecules-25-02944" ref-type="bibr">25</xref>] using zinc finger nuclease-mediated CCR5 knockout, or in CD4
 <sup>+</sup> T cells or HSCs using CRISPR/Cas9 genome editing [
 <xref rid="B26-molecules-25-02944" ref-type="bibr">26</xref>,
 <xref rid="B27-molecules-25-02944" ref-type="bibr">27</xref>]. Viral RNA genome degradation and inhibition of viral gene expression is another promising strategy to prevent the replication of SARS-CoV-2 [
 <xref rid="B28-molecules-25-02944" ref-type="bibr">28</xref>] and HIV-1 [
 <xref rid="B29-molecules-25-02944" ref-type="bibr">29</xref>]. The search for potent low-molecular-weight drugs targeting SARS-CoV-2 is ongoing, but some currently applied treatment strategies include the use of some known drugs such as remdesivir, chloroquine, umifenovir, and some antiretroviral drugs (darunavir, lopinavir in combination with ritonavir) [
 <xref rid="B30-molecules-25-02944" ref-type="bibr">30</xref>].
</p>
